Abstracts Archive - Page 875 of 2425 - ACR Meeting Abstracts

Abstract Number: 1749 • 2019 ACR/ARP Annual Meeting
Improving Eye Screening Among Pediatric Rheumatology Patients Receiving Hydroxychloroquine: Experience of a Quaternary Care Center
Ohoud AlAhmed¹, Amanda Way ², Shoghik akoghlanian ², Fatima Barbar-Smiley ², Stephanie Lemle ², Darby MacDonald ², Kelly Wise ², Stacy Ardoin ² and Vidya Sivaraman ³, ¹Nationwide Children's Hospital, Columbu, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Nationwide Children's Hospital and The Ohio State University, Columbus, OH
Background/Purpose: Hydroxychloroquine (HCQ) is commonly used in the treatment of autoimmune diseases. However, its use is associated with progressive irreversible retinal damage and vision loss…
Abstract Number: 1750 • 2019 ACR/ARP Annual Meeting
Pediatric Sjögren Syndrome: A Single-Center Experience
Rachel Randell¹ and Heather Van Mater ¹, ¹Duke University, Durham, NC
Background/Purpose: Sjögren syndrome (SS) is a chronic autoimmune disease of exocrine gland dysfunction that affects up to 4 million adults in the United States. Children…
Abstract Number: 1751 • 2019 ACR/ARP Annual Meeting
A Systematic Literature Review of Efficacy and Safety of Biologic Agents for the Treatment of Juvenile Dermatomyositis
edoardo marrani¹, Sarah Abu Rumeileh ¹, Francesca Tirelli ², Ilaria Maccora ³ and Gabriele Simonini ⁴, ¹Post graduate School of pediatrics, University of Florence, Firenze, Italy, ²Post Graduate School of Pediatrics, University of Florence, Florence, Italy, Firenze, Italy, ³Post Graduate School of Pediatrics, University of Florence, Florence, Italy, Florence, Toscana, Italy, ⁴Anna Meyer Children's Hospital, Flotence, Italy
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare, chronic autoimmune illness characterized by symmetric, proximal muscle damages and involvement of the skin. While first line treatment…
Abstract Number: 1752 • 2019 ACR/ARP Annual Meeting
Is Early Standardized Rituximab Therapy Sufficient for Toddlers with NMDAR Encephalitis?
Hitha Amin¹, Mered Parnes ¹, Christian Niedzwecki ², Sarah Risen ¹ and Eyal Muscal ³, ¹BCM, child neurology, houston, TX, ²BCM, Physical medicine and rehabilitation, houston, TX, ³Baylor College of Medicine, Houston, TX
Background/Purpose: Anti-NMDAR encephalitis may be more prevalent than some forms of viral encephalitis in children. Pediatric rheumatologists are called upon to assist in the diagnosis…
Abstract Number: 1753 • 2019 ACR/ARP Annual Meeting
Are Patterns of Early Disease Severity Predictive of Grade 12 Academic Achievement in Patients with Childhood-onset Chronic Rheumatic Diseases?
Lily SH Lim¹, Okechukwu Ekuma ², Ruth Ann Marrie ¹, Marni Brownell ², Christine Peschken ¹, Carol Hitchon ¹, Kerstin Gerhold ¹ and Lisa Lix ³, ¹University of Manitoba, Winnipeg, MB, Canada, ²Manitoba Center for Health Policy, Winnipeg, MB, Canada, ³University of Manitoba, Winnipeg, Canada
Background/Purpose: Youths with childhood-onset chronic rheumatic diseases (ChildCRD), including juvenile arthritis (JA) and systemic autoimmune rheumatic diseases (SARD), have worse grade 12 standards tests results…
Abstract Number: 1754 • 2019 ACR/ARP Annual Meeting
Comorbidities and Treatments in United States Youth with Chronic Musculoskeletal Pain
Matthew Taylor ¹, Sabrina Gmuca ², Lakshmi Moorthy ³, Alexis Boneparth ⁴ and Daniel Horton³, ¹Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Columbia University Medical Center, New York, NY
Background/Purpose: Chronic musculoskeletal (MSK) pain has been associated with chronic illnesses, including mental disorders, and with high rates of pain medication use, often in referral…
Abstract Number: 1755 • 2019 ACR/ARP Annual Meeting
Improving Adolescent Health Care Transition: Piloting the Transition Readiness Assessment Questionnaire
Meghan Foster¹, Matthew Hollander ², Amanda Kennedy ³, Laura Lewis ⁴, Olivia Thompson ³, Bradley Tompkins ³ and Constance Van Eeghen ⁴, ¹UVMMC, Jericho, VT, ²UVMMC, Burlington, VT, ³UVMMC, Burlington, ⁴UVM, Burlington
Background/Purpose: Successful adolescent health care transition (HCT) is a vital process in providing developmentally appropriate care and minimizing negative outcomes, especially in adolescents with special…
Abstract Number: 1756 • 2019 ACR/ARP Annual Meeting
Health-related Social Media Use by Parents of Children with Rheumatic Diseases
Jonathan Hausmann¹, Vincent Del Gaizo ², Kara Magane ³, Alexandra Marin ⁴, Shannon Malloy ⁵, Sanjay Mishra ⁶, Tory Aquino ⁷, Marc Natter ⁸, Laura Schanberg ⁹ and Elissa Weitzman ⁸, ¹Boston Children's Hospital / Beth Israel Deaconess Medical Center, Boston, MA, ²Childhood Arthritis and Rheumatology Research Alliance, Whitehouse Station, NJ, ³Boston Children’s Hospital, Boston, MA, ⁴Boston Children's Hospital, Boston, MA, ⁵Cure JM Foundation, Seattle, WA, ⁶Seattle Public Schools, Seattle, WA, ⁷Hearing Life, Patterson Heights, PA, ⁸Boston Children’s Hospital / Harvard Medical School, Boston, MA, ⁹Duke University Medical Center, Durham, NC
Background/Purpose: Disease and treatment burdens are high for children living with rheumatic diseases. Pediatric patients and their families lack a mature evidence base to guide…
Abstract Number: 1757 • 2019 ACR/ARP Annual Meeting
Review of Effectiveness of an Intensive Rehabilitation Programme in Managing Strength, Pain and Function in 123 Young People with Rheumatological Conditions
Susan Maillard¹, Kim Noar ² and Lauren Stone ², ¹Great Ormond Street Hospital NHS Foundation Trust, Maidenhead, United Kingdom, ²Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom
Background/Purpose: Young people with Rheumatological conditions often experience ongoing pain, muscle weakness and reduced function despite modern medication. The unit at Great Ormond Street Hospital…
Abstract Number: 1758 • 2019 ACR/ARP Annual Meeting
Development of Ultrasound Detectable Arthritis Among ACPA Positive Subjects with Musculoskeletal Symptoms: The Risk RA Prospective Study
Aase Hensvold¹, Yogan Kisten ², Alexandra Circiumaru ¹, Monika Hansson ³, Meng Sun ¹, Guozhong Fei ⁴, Nancy Vivar ², Erik af Klint ², Hamed Rezaei ², Lars Klareskog ³, Aleksandra Antovic ⁵ and Anca Catrina ³, ¹Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, ²Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ³Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁴Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden, Stockholm, Sweden, ⁵Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Studies have shown that anti-citrullinated protein antibodies (ACPA) are a risk factor for the development of arthritis. We aimed to investigate in a prospective…
Abstract Number: 1759 • 2019 ACR/ARP Annual Meeting
Methotrexate in Patients with Hand Erosive Osteoarthritis Refractory to Usual Treatments: A Randomized, Double-blind, Placebo-controlled Trial
stéphanie Ferrero ¹, Ruth Wittoek ², Edem Allado ³, Coralie Cruzel ⁴, Véronique Breuil ¹, Liana Euller Ziegler ⁵, Damien louille ⁶, Christian Roux⁷ and Joel Kremer ⁸, ¹University of Nice, nice, France, ²Ghent University Hospital, Gent University, Gent, Belgium, ³Centre Hospitalier Universitaire de Nancy, Nancy, France, ⁴Université Cote d'Azur, nice, France, ⁵PUPH CHU NICE, nice, France, ⁶Université Cote d'Azur, Nancy, France, ⁷Université Cote d'Azur, Nice, ⁸Albany Medical College, Albany, NY
Background/Purpose: No studies have assessed the effect of methotrexate (MTX) in osteoarthritis of the hand (HOA). The purpose of our study was to examine the…
Abstract Number: 1760 • 2019 ACR/ARP Annual Meeting
Six-week Treatment with Low-dose Prednisolone in Patients with Painful Hand Osteoarthritis (HOPE): Results from a Randomised Double-blind Placebo-controlled Trial
Féline Kroon¹, Marion Kortekaas ¹, Annelies Boonen ², Stephan Böhringer ³, Monique Reijnierse ¹, Frits R Rosendaal ³, Naghmeh Riyazi ⁴, Mirian Starmans ⁵, Franktien Turkstra ⁶, Jende van Zeben ⁷, CF Allaart ⁸ and Margreet Kloppenburg ³, ¹Leiden University Medical Center, Leiden, Netherlands, ²Maastricht University Medical Center, Maastricht, Netherlands, ³Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ⁴Haga Hospital, The Hague, Netherlands, ⁵Zuyderland Medical Center, Heerlen, Netherlands, ⁶Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ⁷Sint Franciscus Vlietland Groep, Rotterdam, Netherlands, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands
Background/Purpose: Hand osteoarthritis (OA) is a prevalent joint disease with high disease-burden in need for effective therapeutic options. Studies have shown that synovial inflammation is…
Abstract Number: 1761 • 2019 ACR/ARP Annual Meeting
The Prospective Open Label Preventive Approach to Congenital Heart Block with Hydroxychloroquine (PATCH) Study Demonstrates a Reduction in the Recurrence Rate of Advanced Block
Peter Izmirly¹, Mimi Kim ², Nathalie Costedoat-Chalumeau ³, Deborah Friedman ⁴, Amit Saxena ⁵, Joshua Copel ⁶, Rebecca Cohen ¹, Mala Masson ¹, Tishaun Middleton ¹, Kimberly Robins ¹, Robert Clancy ¹ and Jill Buyon ¹, ¹NYU School of Medicine, New York, ²Albert Einstein College of Medicine, Bronx, NY, ³Cochin University Hospital, Paris, France, ⁴New York Medical College, Valhalla, ⁵New York University School of Medicine, New York, NY, ⁶Yale School of Medicine, New Haven
Background/Purpose: Based on encouraging bench to bedside results including experimental evidence supporting Toll-like receptor signaling in the pathogenesis of CHB, a case control study demonstrating…
Abstract Number: 1762 • 2019 ACR/ARP Annual Meeting
UV Light Induces Acute Type I Interferon Production in the Skin and Blood Which Is cGAS Dependent
Sladjana Skopelja-Gardner¹, Jie An ², Xizhang Sun ², Lena Tanaka ², Joyce Tai ², Payton Hermanson ², Masaoki Kawasumi ² and Keith Elkon ², ¹University of Washington, Seattle, WA, ²University of Washington, Seattle
Background/Purpose: Interferon response genes (ISG) are strongly expressed in the skin of many patients with systemic lupus erythematosus (SLE). Since plasmacytoid dendritic cells (pDC) are…
Abstract Number: 1763 • 2019 ACR/ARP Annual Meeting
A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus
Richard Furie¹, Eric Morand ², Ian Bruce ³, Susan Manzi ⁴, Kenneth Kalunian ⁵, Edward Vital ⁶, Theresa Lawrence-Ford ⁷, Ramesh Gupta ⁸, Falk Hiepe ⁹, Mittermayer Santiago ¹⁰, Philip Brohawn ¹¹, Anna Berglind ¹² and Raj Tummala ¹³, ¹Zucker School of Medicine at Hofstra/Northwell, New York, NY, ²Monash University, Melbourne, Victoria, Australia, ³University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ⁴Allegheny Health Network, Pittsburg, PA, ⁵Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ⁶University of Leeds, Leeds, United Kingdom, ⁷North Georgia Rheumatology, Lawrenceville, GA, ⁸Baptist Memorial Hospital-Memphis, Memphis, TN, ⁹Charité University Hospital Berlin, Berlin, Germany, ¹⁰Bahiana School of Medicine and Public Health, Bahia, Brazil, ¹¹AstraZeneca, Gaithersburg, MD, ¹²AstraZeneca, Gothenburg, Sweden, ¹³AstraZeneca, Gaithersburg, MD, USA, Gaithersburg, MD
Background/Purpose: In a phase 2 study in SLE patients (pts), substantial efficacy was observed with anifrolumab, a human monoclonal antibody that binds the type I…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].